Eltrombopag for Chemotherapy-induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia Clinical Trial

Official title: Eltrombopag for Chemotherapy-induced Thrombocytopenia: a Prospective Multi-center One-arm Study in Solid Tumors

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors

Clinical Trial Description

This is a single-arm study to evaluate the safety and efficacy of eltrombopag to treat chemotherapy-induced thrombocytopenia（CIT）. These subjects have been treated with recombinant human thrombopoietin（rhTPO） or interleukin 11（IL-11） before, the platelets can rise to normal or reach the effective standard, but after the re-application, the effective standard is not reached, or the effective standard is still not reached after the rhTPO 300U/kg/d treatment for 14 days. The investigator will assess the changes of the platelet counts after the treatment of eltrombopag from week 1 to week 24, and observe incidence of adverse events during the treatment of eltrombopag.The investigator will complete the 4 weeks safety visits（once a week），if the subjects end or withdraw from the clinical trial. Patients with chemotherapy-induced thrombocytopenia who had the same inclusion and exclusion criteria in the same period or in the past will be compared with the efficacy and safety of supportive treatment in the same period or history, so as to preliminarily explore and evaluate the efficacy and safety of eltrombopag treatment. ;

Related Conditions & MeSH terms

• Chemotherapy-induced Thrombocytopenia
• Eltrombopag
• Thrombocytopenia

• NCT number: NCT04600960
• Study type: Interventional
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Yunfei Chen, MD
• Phone: +86-22-23909009
• Email: chenyunfei@ihcams.ac.cn
• Status: Recruiting
• Phase: Phase 2
• Start date: December 31, 2020
• Completion date: December 31, 2023